DEM Biopharma, Inc.

DEM Biopharma is a biotechnology company focused on developing next-generation immunotherapies designed to harness the power of the innate immune system to combat cancer. Their innovative approach targets "don't eat me" (DEM) and "eat me" (EM) signals on cancer cells and macrophages, aiming to trigger a targeted immune response that eliminates tumors. Their proprietary CHoMP™ platform utilizes inter-cellular CRISPR screening with tumor cells, macrophages, and other innate immune cells to identify novel DEM and EM signals.

DEM Biopharma was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik. They have assembled a strong leadership team, including CEO Nenad Grmusa and CSO Christophe Quéva, and boast a notable scientific advisory board featuring renowned experts in the field. The company has secured significant funding, raising $70 million in its initial financing round. With its cutting-edge approach and a team of leading scientists, DEM Biopharma is poised to make a significant impact in the fight against cancer.

DEM Biopharma is a biotechnology company focused on developing the next generation of immunotherapies for cancer treatment. Their innovative approach involves harnessing the power of the innate immune system, specifically macrophages and other myeloid effector cells, to eliminate tumors. They achieve this by targeting novel "don't eat me" (DEM) and "eat me" (EM) signals on both cancer cells and macrophages. DEM Bio leverages its proprietary CHoMP™ platform to identify these unexplored DEM and EM signals through systematic and unbiased inter-cellular CRISPR screening, ultimately aiming to revolutionize cancer immunotherapy.

DEM Biopharma promotes a culture of scientific innovation and collaboration. The company is driven by a mission to eliminate cancer by targeting novel "don't eat me" and "eat me" signals on cancer cells and macrophages. This focus on cutting-edge research is evident in their team of distinguished scientists, their commitment to the CHoMP™ platform, and their collaborations with leading institutions. Their website also highlights a diverse team of talented individuals from various backgrounds, suggesting a welcoming and inclusive work environment.